Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Ali Saffaei and Payam Tabarsi.
Ali Saffaei
Connection Strength
1.278
Payam Tabarsi
  1. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial. Int Immunopharmacol. 2021 Jan; 90:107205.
    View in: PubMed
    Score: 0.228
  2. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Int Immunopharmacol. 2020 Nov; 88:106869.
    View in: PubMed
    Score: 0.224
  3. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int Immunopharmacol. 2020 Aug; 85:106688.
    View in: PubMed
    Score: 0.221
  4. Tocilizumab administration in a refractory case of COVID-19. Int J Antimicrob Agents. 2020 Aug; 56(2):106043.
    View in: PubMed
    Score: 0.221
  5. Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces. Iran J Pharm Res. 2020; 19(1):1-2.
    View in: PubMed
    Score: 0.215
  6. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021 Apr 15; 897:173947.
    View in: PubMed
    Score: 0.058
  7. Extracorporeal membrane oxygenation and COVID-19: The causes of failure. J Card Surg. 2020 Oct; 35(10):2838-2843.
    View in: PubMed
    Score: 0.056
  8. A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol. Iran J Pharm Res. 2020; 19(1):31-36.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.